Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 30

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 30
---
 adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.

A key part of our business plan is to establish
and cultivate long-term relationships with strategic partners, including collaborations with global health organizations, like WHO and
NIH, NGOs, and government health organizations. These partnerships can facilitate market access, drive adoption, and support public health
initiatives. We must successfully contract with these and other third parties to develop and market our novel technology. We are evaluating
additional potential partnerships and collaborative agreements as a way to further fund operations, but there is no assurance we will
be able to secure partnerships or other arrangements and to negotiate commercially acceptable licensing or other agreements for the future
exploitation of our novel technology, including the continued clinical development, manufacture or marketing of our novel technology.
If we are unable to successfully contract for these services, or if arrangements for these services are terminated, we may have to delay
our commercialization program for our novel technology, which will adversely affect our ability to generate operating revenues.

The success of our business operations is dependent on our ability to successfully develop our products and to complete clinical programs. We cannot assure you that we will successfully develop any products, or if we do, that they will be commercially successful.

Our ability to achieve and sustain operating
profitability depends on our ability, directly or with strategic partners, to successfully commercialize our products in Europe, Asia
and in the US. This will depend in large part on our ability to commence, execute and complete clinical programs and obtain regulatory
approvals for our products in these geographies.

Clinical trials are necessary before we can seek
regulatory approval to sell our products. We cannot assure you that we will receive approval for our products in the United States or
in other countries or, if approved, that we or a partner will achieve a significant level of sales, or that we develop any products. If
we fail to partner, develop or commercialize our products, we may be forced to curtail or cease operations.

We are also in the relatively early pre-clinical
stages of research and development with the vaccine and ARB new product candidates. These new indications and product candidates will
require significant costs to advance through the development stages. Even if such product candidates are advanced through clinical trials,
the results of such trials may not gain FDA approval. Even if approved, our products may not be commercially successful.

<div align='center'>15</div>

Risks Related to Protection of our Intellectual Property